Uric acid levels and the risk of Contrast Induced Nephropathy inpatients undergoing coronary angiography or PCI

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 25, Issue 2, 2015, Pages 181-186

  Barbieri, L ^a   Verdoia, M ^a   Schaffer, A ^a   Cassetti, E ^a   Marino, P ^a   Suryapranata, H ^b   De Luca, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Contrast Induced Nephropathy; Coronary angiography; Hyperuricemia; Percutaneous interventions

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOPROMIDE; IOVERSOL; NITRIC ACID DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; URIC ACID;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; BIOCHEMISTRY; CONGESTIVE CARDIOMYOPATHY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; BLOOD; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; COMPLICATION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; RISK FACTOR; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DIURETICS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; KIDNEY DISEASES; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; REACTIVE OXYGEN SPECIES; RISK FACTORS; TRIGLYCERIDES; URIC ACID;

EID: 84922008080     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.08.008     Document Type: Article

References (30)

1. McCullough P.A. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008, 51:1419-1428.
2. James M.T., Gali W.A., Tonelli M., Faris P., Knudtson M.L., Pannu N., et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. Kidney Int 2010, 78:803-809.
3. McCullough P.A., Soman S.S. Contrast-induced nephropathy. Crit Care Clin 2005, 21(2):261-280.
4. Mehran R., Aymong E., Nikolsky E., Lasic Z., Iakovou I., Fahy M., et al. A simple risk score for prediction of contrast induced nephropathy after percutaneous coronary intervention. J Am Coll Cardiol 2004, 44:1393-1399.
5. Maeder M., Klein M., Fehr T., Rickli H. Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 2004, 44:1763-1771.
6. Navarese E.P., Kubica J., Castriota F., Gibson C.M., De Luca G., Buffon A., et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. EuroIntervention 2011, 7:985-994.
7. De Luca G., Dirksen M.T., Spaulding C., Kelbaek H., Schalij M., Thuesen L., et al. Drug-eluting stent in primary angioplasty (DESERT) cooperation. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med 2012, 172:611-621.
8. De Luca G., Navarese E.P., Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol 2013, 166(3):606-612.
9. De Luca G., Verdoia M., Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis 2012, 222(2):426-433.
10. De Luca G., Smit J.J., Ernst N., Suryapranata H., Ottervanger J.P., Hoorntje J.C., et al. Impact of adjunctive tirofiban administration on myocardial perfusion and mortality in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. Thromb Haemost 2005, 93:820-823.
11. Navarese E.P., De Luca G., Castriota F., Kozinski M., Gurbel P.A., Gibson C.M., et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011, 9:1902-1915.
12. Moreau J.F., Droz D., Noel L.H., Leibowitch J., Jungers P., Michel J.R. Tubular nephrotoxicity of water-soluble iodinated contrast media. Invest Radiol 1980, 15:S54-S60.
13. Goldenberg I., Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005, 172:1461-1471.
14. Lazzeri C., Valente S., Chiostri M., Sori A., Bernardo P., Gensini G.F. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol 2010, 138:206-209.
15. Elbasan Z., Şahin D.Y., Gür M., Kuloğlu O., Kivrak A., Içen Y.K., et al. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology 2014 Jan, 65(1):37-42.
16. Filiopoulus V., Hadjiyannakos D., Vlassopoulos D. New insights into uric acid effects on the progression and prognosis of chronic kidney disease. Ren Fail 2012, 34(4):510-520.
17. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 Feb, 39(2 Suppl. 1):S1-S266.
18. De Luca G., van 't Hof A.W., Ottervanger J.P., Hoorntje J.C., Gosselink A.T., Dambrink J.H., et al. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005, 26:662-666.
19. De Luca G., Suryapranata H., Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status. Prog Cardiovasc Dis 2008, 50(5):352-382.
20. De Luca G., Bellandi F., Huber K., Noc M., Petronio A.S., Arntz H.R., et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis. J Thromb Haemost 2011, 9:2361-2370.
21. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., et al. Risk prediction of contrast induced nephropathy. Am J Cardiol 2006, 98(Suppl.):27K-36K.
22. Marenzi G., De Metrio M., Rubino M., Lauri G., Cavallero A., Assanelli E., et al. Acute hyperglycemia and contrast induced nephropathy in primary percutaneous coronary intervention. Am Heart J 2010, 160:1170-1177.
23. Kang D.H., Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005 Jan, 25(1):43-49. [Review].
24. Nieto F., Iribarren C., Gross M.D., Comstock G.W., Cutler R.G. Uric acid and serum antioxidant capacity: a reaction to atherosclerosis?. Atherosclerosis 2000, 148:131-139.
25. Waring W.S., McKnight J.A., Webb D.J., Maxwell S.R. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006, 55:3127-3132.
26. De Luca G., Secco G.G., Santagostino M., Venegoni L., Iorio S., Cassetti E., et al. Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. Nutr Metab Cardiovasc Dis 2012, 22:426-433.
27. Postlethwaite A.E., Kelley W.N. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med 1971 Jun, 74(6):845-852.
28. Mudge G.H. Uricosuric action of cholecystographic agents: possible nephrotoxicity. N Engl J Med 1971, 284:929-933.
29. Toprak O., Cirit M., Esi E., Postaci N., Yesil M., Bayata S. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv 2006 Feb, 67(2):227-235.
30. Saritemur M., Turkeli M., Kalkan K., Tanboga I˙.H., Aksakal E. Relation of uric acid and contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED. Am J Emerg Med 2013, 32(2):119-123.